Hepatitis B e-Antigen Test

Hepatitis B e-antigen (HBeAg) is a viral protein secreted into the bloodstream during active hepatitis B virus (HBV) infection. Although it is not required for the virus to replicate, its presence serves as a reliable indicator that the virus is replicating at high levels and that the infected person is highly contagious. This makes HBeAg a key marker for assessing how active the infection is and whether treatment or preventive measures are needed.

Biologically, HBeAg plays an important role in helping the virus evade the immune system. It acts as a tolerogen, which means it can “train” the immune system, especially in newborns, not to recognize the virus as a threat. This is particularly concerning in mother-to-child transmission during birth, where the presence of HBeAg significantly raises the risk that a newborn will develop chronic HBV infection. By suppressing immune responses, including T cell activity and inflammatory signaling, HBeAg helps the virus persist without immediately triggering a strong immune attack.

Clinically, HBeAg is used to help determine the phase of HBV infection. When HBeAg is present (HBeAg-positive), it usually means the virus is actively replicating and liver inflammation is ongoing or likely to develop. Over time, some patients lose HBeAg and develop antibodies against it (anti-HBe), a process known as seroconversion. This change often signals a transition to a less active form of the infection with lower viral levels and improved liver health. However, some patients remain infected with HBV even after losing HBeAg. This is known as HBeAg-negative chronic hepatitis B, often due to viral mutations. These cases can still involve active liver disease and require close monitoring and treatment.

The detection of HBeAg is also essential for managing HBV during pregnancy. Because high HBV DNA levels and HBeAg positivity strongly predict mother-to-child transmission, testing pregnant women for HBeAg can guide the need for antiviral treatment in the third trimester. In many lower-resource settings, HBeAg testing serves as a practical substitute for HBV DNA testing to assess this risk.